Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure S4 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
  1. Home
  2. Publications
  3. Supplementary Figure S4 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

Supplementary Figure S4 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

Authors:
  • FSFlurina A.M. Saner
    Flurina A.M. Saner
  • KTKazuaki Takahashi
    Kazuaki Takahashi
  • TBTimothy Budden
    Timothy Budden
  • APAhwan Pandey
    Ahwan Pandey
  • DADinuka Ariyaratne
    Dinuka Ariyaratne
  • TZTibor A. Zwimpfer
    Tibor A. Zwimpfer
  • NMNicola S. Meagher
    Nicola S. Meagher
  • SFSian Fereday
    Sian Fereday
  • LTLaura Twomey
    Laura Twomey
  • KPKathleen I. Pishas
    Kathleen I. Pishas
  • THTherese Hoang
    Therese Hoang
  • ABAdelyn Bolithon
    Adelyn Bolithon

Open Access
Publisher website
Google Scholar
  • 15 August 2024
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.26711103
Abstract
Supplementary Figure S4. HGSC cell lines with innate RB1 and/or BRCA1 alterations.
Keywords
  • SUPPLEMENTARY FIGURE
  • BRCA DEFICIENCY
  • DEFICIENCY PREDICTS
  • PREDICTS ENHANCED
  • ENHANCED IMMUNOLOGIC
  • IMMUNOLOGIC RESPONSE
  • LONG-TERM SURVIVAL
  • TUBO-OVARIAN HIGH-GRADE
  • HIGH-GRADE SEROUS
  • SEROUS CARCINOMA
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.